4basebio (LON:4BB) Releases Quarterly Earnings Results

4basebio (LON:4BB) issued its earnings results on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

4basebio Stock Down 0.5%

LON 4BB traded down GBX 2.70 on Wednesday, reaching GBX 559.80. The company had a trading volume of 115 shares, compared to its average volume of 1,346. The company’s fifty day moving average is GBX 512.25 and its 200-day moving average is GBX 510.12. The firm has a market capitalization of £86.69 million, a price-to-earnings ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. 4basebio has a 1-year low of GBX 420 and a 1-year high of GBX 820.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reduced their price objective on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, 4basebio has a consensus rating of “Buy” and an average price target of GBX 1,400.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.